Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08653944 on Gastric Emptying in Overweight or Obese Adults
NCT07508241Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2026
- Primary completion
- Jan 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-08653944 in obesity (6 arms), sponsored by Pfizer. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve and 1 more. Started Mar 2026; status: active, not recruiting.
02
Drugs
PF-08653944
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07508241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07508241.